drugset / Trial / NCT00650182

A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant

NCT00650182

Phase 2 Completed 406 enrolled Alza Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective was to evaluate the safety of D-TRANS fentanyl with naltrexone HCl system compared to the Duragesic (fentanyl transdermal system) in opioid tolerant patients.

Timeline

Start
2003-01
Primary completion
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 25 ug Other
Subject Fentanyl Other / unclassified 50 ug Other
Subject Fentanyl Other / unclassified 75 ug Other
Subject Fentanyl Other / unclassified 100 ug Other
Subject Naltrexone Small molecule Other

Indications